Skip to main content
OpenTrials
Completed

NCT Number: NCT02600845

ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)

This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management System over a period of 6 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 1 Autoimmune Diseases Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Montgomery, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of type 1 or type 2 diabetes for greater than or equal to (>=) 6 months
  • Currently using insulin as a component of the diabetes therapy
  • Allow and be able to provide self-monitoring of blood glucose (SMBG) data at least 1 month prior to study start
  • SMBG frequency as confirmed by site SMBG data download of participants meter(s): Basal insulin treated participants - SMBG >=5 times per week and Multiple dose insulin participants - SMBG >=2 times per day
  • Glycosylated hemoglobin (HbA1c) of >=7.5 percentage (per local laboratory obtained less than or equal to [<= 3] months of Baseline)
  • Able to read and write in English language
  • Currently using a Smartphone and have experience with downloading at minimum one application
  • Smartphone compatibility; must be able to download the ACCU-CHEK Connect system application accordingly
  • Naive to the ACCU-CHEK Connect system
  • Willing to comply with study procedures

Exclusion criteria

  • Treatment with insulin pump therapy
  • Any use of continuous glucose monitoring (CGM) to manage their diabetes during the course of the study
  • Visually impaired
  • Women who are pregnant, lactating or planning to become pregnant during the study period
  • Diagnosed with any clinically significant condition (for example anemia, major organ system disease, infections, psychosis or cognitive impairment)
  • Participant requires chronic steroid in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy
  • Participant is the investigator or any sub-investigator, general practitioner, practice staff, pharmacist, research assistant or other staff or relative of those directly involved in the conduct of the study and design of the protocol

Treatment and study plan

ACCU-CHEK

Device

ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.

Primary outcomes

  1. Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24

    Time frame: Week 24

    The Diabetes Treatment Satisfaction Questionnaire for change from Baseline (DTSQc) to study end contains 6 items which can be rated from -3='much worse now' to 3='much better now'). The total score is the sum of the scores of the 6 items and ranges from -18 to 18. A higher score indicates more satisfaction. This questionnaire was administered at the end of the study (Week 24) only.

Secondary outcomes

  1. Change From Baseline to Week 24 in Diabetes Distress Scale (DDS) Score

    Time frame: Baseline, Week 24

    Participants rated their level of diabetes distress by answering 17 questions in in the following areas: Regimen-related Distress, Emotional Burden, Diabetes-related Interpersonal Distress and Physician-related Distress (PD) on a 6-point scale: 1=Not a problem to 6=A very serious problem. The Average Total score ranged from 1 (best) to 6 (worst). Results were calculated using a Linear Mixed Model with study group, visit, group-by-visit interaction, baseline DDS, gender, age, and race as fixed effects; and site and subject as random effects. A negative change from Baseline indicated improvement.

  2. Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24

    Time frame: Baseline, Weeks 12 and 24

    Assessment of HbA1c is an indicator of long-term control of diabetes.

  3. Mean Change From Baseline to Week 24 in Percentage of Glucose Readings in Target Range

    Time frame: Baseline, Week 24

    Glucose target range was specified as 70-180 milligrams per deciliter (mg/dL).

  4. Change From Baseline to Week 24 in Mean Blood Glucose Level

    Time frame: Baseline, Week 24

    Blood glucose is a type of sugar in blood and is measured to assess a participant's control of diabetes.

  5. Change From Baseline to Week 24 in Glycemic Variability

    Time frame: Baseline, Week 24

    Glycemic variability refers to swings in blood glucose levels. Mean glycemic variability is expressed as a standard deviation of blood glucose data. A negative number indicates a decrease in glucose variability. A positive number indicates and increase in glucose variability.

  6. Incidence of Hypoglycemia

    Time frame: Baseline, Weeks 12 and 24

    A hypoglycemic reading was defined as a glucose value that fell below the 70 mg/dL level. The incidence of hypoglycemia was defined as the number of hypoglycemic readings in the interval divided by the total number of blood glucose checks in the interval.

  7. Number of Participants With Competency in Self-monitoring of Blood Glucose (SMBG) at Week 24

    Time frame: Week 24

    Competency was defined as appropriate response to high and low glucose values.

  8. Percent of Follow-Up Visits With Sufficient SMBG Data

    Time frame: Up to Week 24

    Sufficient SMBG data is based on the ability of the healthcare provider to make informed decisions regarding therapy adjustments.

  9. Change From Baseline in the Number of Blood Glucose Checks at Weeks 12 and 24

    Time frame: Baseline, Weeks 12 and 24

    An increase in the number of blood glucose checks indicates more glycemic control.

  10. Change From Baseline in Mean Daily Self-Monitoring of Blood Glucose (SMBG) Frequency at Weeks 12 and 24

    Time frame: Baseline, Weeks 12 and 24

    An increase in SMBG frequency indicates more glycemic control. The average number of daily SMBG measurements per interval was calculated based on the total number of blood glucose readings recorded during the study visit interval.

  11. Percentage of Blood Glucose Tagged Data

    Time frame: Weeks 12 and 24

    Tagged data specifies the timing of blood glucose recording and includes: fasting, before breakfast, after breakfast, before lunch, after lunch, before dinner, after dinner, and bedtime. The percentage of blood glucose tagged data per interval was calculated as the total number of tagged blood glucose readings during the interval divided by the total number of readings within the interval.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Collaborators

  • Roche Diabetes Care

Registry information

Official study title

ACCU-CHEK Connect Personal Diabetes Management Study (PDM)

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Nov 9, 2015
Registry last updated
Nov 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.